|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hassan MS, Ansari J, Spooner D and Hussain
SA: Chemotherapy for breast cancer (Review). Oncol Rep.
24:1121–1131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Driscoll L and Clynes M: Biomarkers and
multiple drug resistance in breast cancer. Curr Cancer Drug
Targets. 6:365–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ng EK, Wong CL, Ma ES and Kwong A:
MicroRNAs as new players for diagnosis, prognosis, and therapeutic
targets in breast cancer. J Oncol. 2009:3054202009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Amponsah PS, Fan P, Bauer N, Zhao Z,
Gladkich J, Fellenberg J and Herr I: microRNA-210 overexpression
inhibits tumor growth and potentially reverses gemcitabine
resistance in pancreatic cancer. Cancer Lett. 388:107–117. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ao X, Nie P, Wu B, Xu W, Zhang T, Wang S,
Chang H and Zou Z: Decreased expression of microRNA-17 and
microRNA-20b promotes breast cancer resistance to taxol therapy by
upregulation of NCOA3. Cell Death Dis. 7:e24632016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Zhu ST, Wang X, Deng J, Li WH,
Zhang P and Liu BS: MiR-200c regulates tumor growth and
chemosensitivity to cisplatin in osteosarcoma by targeting AKT2.
Sci Rep. 7:135982017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cochrane DR, Howe EN, Spoelstra NS and
Richer JK: Loss of miR-200c: A marker of aggressiveness and
chemoresistance in female reproductive cancers. J Oncol.
2010:8217172010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen J, Tian W, Cai H, He H and Deng Y:
Down-regulation of microRNA-200c is associated with drug resistance
in human breast cancer. Med Oncol. 29:2527–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fong H, Hohenstein KA and Donovan PJ:
Regulation of self-renewal and pluripotency by Sox2 in human
embryonic stem cells. Stem Cells. 26:1931–1938. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leis O, Eguiara A, Lopez-Arribillaga E,
Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R
and Martin AG: Sox2 expression in breast tumours and activation in
breast cancer stem cells. Oncogene. 31:1354–1365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alonso MM, Diez-Valle R, Manterola L,
Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, de Munain
Lopez A, Sampron N, et al: Genetic and epigenetic modifications of
Sox2 contribute to the invasive phenotype of malignant gliomas.
PLoS One. 6:e267402011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rudin CM, Durinck S, Stawiski EW, Poirier
JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory
J, et al: Comprehensive genomic analysis identifies SOX2 as a
frequently amplified gene in small-cell lung cancer. Nat Genet.
44:1111–1116. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li D, Zhao LN, Zheng XL, Lin P, Lin F, Li
Y, Zou HF, Cui RJ, Chen H and Yu XG: Sox2 is involved in paclitaxel
resistance of the prostate cancer cell line PC-3 via the PI3K/Akt
pathway. Mol Med Rep. 10:3169–3176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piva M, Domenici G, Iriondo O, Rábano M,
Simões BM, Comaills V, Barredo I, López-Ruiz JA, Zabalza I, Kypta R
and Vivanco MD: Sox2 promotes tamoxifen resistance in breast cancer
cells. EMBO Mol Med. 6:66–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wuebben EL, Wilder PJ, Cox JL, Grunkemeyer
JA, Caffrey T, Hollingsworth MA and Rizzino A: SOX2 functions as a
molecular rheostat to control the growth, tumorigenicity and drug
responses of pancreatic ductal adenocarcinoma cells. Oncotarget.
7:34890–34906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mukherjee P, Gupta A, Chattopadhyay D and
Chatterji U: Modulation of SOX2 expression delineates an end-point
for paclitaxel-effectiveness in breast cancer stem cells. Sci Rep.
7:91702017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen
S, Wu Q, Chen C and Wang Z: MiR-125b regulates
epithelial-mesenchymal transition via targeting Sema4C in
paclitaxel-resistant breast cancer cells. Oncotarget. 6:3268–3279.
2015.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pogribny IP, Filkowski JN, Tryndyak VP,
Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs
and their targets are associated with acquired resistance of MCF-7
breast cancer cells to cisplatin. Int J Cancer. 127:1785–1794.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: miR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hamano R, Miyata H, Yamasaki M, Kurokawa
Y, Hara J, Moon JH, Nakajima K, Takiguchi S, Fujiwara Y, Mori M and
Doki Y: Overexpression of miR-200c induces chemoresistance in
esophageal cancers mediated through activation of the Akt signaling
pathway. Clin Cancer Res. 17:3029–3038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimono Y, Zabala M, Cho RW, Lobo N,
Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao C, Peng FH and Peng LK: MiR-200c
sensitizes clear-cell renal cell carcinoma cells to sorafenib and
imatinib by targeting heme oxygenase-1. Neoplasma. 61:680–689.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop-a motor of cellular plasticity in development and
cancer. EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hill L, Browne G and Tulchinsky E:
ZEB/miR-200 feedback loop: At the crossroads of signal transduction
in cancer. Int J Cancer. 132:745–754. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peng C, Li N, Ng YK, Zhang J, Meier F,
Theis FJ, Merkenschlager M, Chen W, Wurst W and Prakash N: A
unilateral negative feedback loop between miR-200 microRNAs and
Sox2/E2F3 controls neural progenitor cell-cycle exit and
differentiation. J Neurosci. 32:13292–13308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu YX, Yuan L, Xue XL, Zhou M, Liu Y,
Zhang C, Li JP, Zheng L, Hong M and Li XN: Regulation of colorectal
carcinoma stemness, growth, and metastasis by an
miR-200c-Sox2-negative feedback loop mechanism. Clin Cancer Res.
20:2631–2642. 2014. View Article : Google Scholar : PubMed/NCBI
|
